Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Denmark-based drugmaker Novo Nordisk said on Tuesday it will stop a trial studying Ozempic, its popular diabetes and weight-loss drug, to treat renal impairment in diabetes patients, as its independent data monitoring board concluded the drug had met efficacy criteria in an interim analysis.

Novo Nordisk to stop Ozempic trial to treat renal impairment early

Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis Bagsværd, Denmark, 10 October 2023 – Novo Nordisk today announced the decision to stop the kidney outcomes trial FLOW (Effect of semaglutide versus placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease). The decision to stop the trial is based on a recommendation from the independent Data Monitoring Committee (DMC) concluding that the results from an interim analysis met certain pre-specified criteria for stopping the trial early for efficacy.

Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis

How Ozempic and Wegovy turned Novo Nordisk into a $400 billion company

Eli Lilly

The number of U.S. employers who cover obesity medications, including Wegovy from Novo Nordisk that belongs to a class of GLP-1 drugs, could nearly double next year, according to a survey. The survey of 502 employers by Accolade , a company that provides healthcare programs for employers, and research firm Savanta said 43% of the employers it polled could cover GLP-1 drugs in 2024 compared to 25% that cover them now.

U.S. employers covering weight-loss drugs could nearly double in 2024 - survey

Pfizer

Pfizer has been actively acquiring companies as it looks to bolster its future growth prospects. Novo Nordisk's top weight-loss drug has more than quadrupled sales and there's more growth ahead.

Better Growth Stock: Novo Nordisk vs. Pfizer

Ozempic and Mounjaro are key drugs for Novo Nordisk and Eli Lilly, respectively. Both treat most of the same conditions, and both are major drivers of earnings.

2 Reasons Why Eli Lilly's Mounjaro Might Beat Novo Nordisk's Ozempic, and 2 Reasons Why It Might Not

Medicines in the same class as Novo Nordisk's popular weight-loss therapy Wegovy may carry an increased risk of pancreatitis, intestinal blockage, and stomach paralysis compared to an older obesity drug, according to a study published on Thursday.

Wegovy class has higher GI side effect risk than older weight loss drug in study

The study comes as Novo Nordisk's Wegovy, Ozempic and similar treatments skyrocket in popularity in the U.S. for causing dramatic weight loss over time.

Weight loss drugs may be linked to stomach paralysis, other rare but severe issues, study says

One of Novo Nordisk's (NYSE:NVO) US patents for its blockbuster weight-loss drugs Ozempic and Wegovy will be reviewed by the US Patent Office after it was questioned by generic drugmaker Mylan Pharmaceuticals, which had two other petitions over the drugs rejected earlier in the week. Mylan wants to make generic versions of the drugs.

Novo Nordisk's Wegovy and Ozempic US patents to be examined by appeal board

Costco

Mastercard

Novo Nordisk, Mastercard, and Costco provide investors with recurring income and good growth. These businesses have been performing well over the years and have more potential ahead.

3 Dividend Stocks That Turned $25,000 into $100,000 in 10 Years -- and None of Them Is a Tech Stock

The whirlwind success of weight-loss treatment Wegovy is providing a bonanza not just for its developer, Novo Nordisk , but also for its home country of Denmark.

Focus: Novo Nordisk's Wegovy bonanza looms large in Denmark

Europe's largest drugs company, Novo Nordisk (NYSE:NVO), told investors its once-monthly injection, Rivfloza, has received approval from the US Food and Drug Administration (FDA) for treating a rare genetic kidney condition known as primary hyperoxaluria. Rivfloza employs RNA interference technology (RNAi) to silence or neutralise genes that contribute to the disease.

Novo Nordisk receives US regulatory go ahead for kidney treatment

A U.S. Patent Office tribunal on Monday rejected challenges to two key patents owned by Novo Nordisk covering the active ingredient in its weight-loss and diabetes drugs Wegovy and Ozempic brought by a generic drugmaker that is hoping to sell generic versions of the blockbuster medications.

US Patent Office won't review two Novo Nordisk patents for Wegovy, Ozempic

AstraZeneca

Bristol-Myers

Merck

A federal judge dealt a blow to hopes for a near-term injunction to halt the federal government plan to let Medicare to pay less for a few expensive medicines.

Big Pharma Can't Stop the Price-Negotiation Program. What's Next.

Novo Nordisk said on Monday the U.S. Food and Drug Administration (FDA) had approved its therapy to treat a rare genetic condition that affects the kidneys.

US FDA approves Novo Nordisk's therapy for rare genetic condition

Thermo Fisher Scientific

Biotech stocks have had a rough post-pandemic. In a year where the S&P500 is up more than 10% year to date, the biotech sector is still negative to flat.

Stable Giants: 3 Bigwig Biotech Stocks for Consistent Returns

Arthur J. Gallagher & Co.

Booking Hlds

After a run, stocks can offer a new buying opportunity with a pullback to the 50-day line. Novo Nordisk and 4 S&P 500 stocks have done that.

These 5 Stocks Are Setting Up This Buying Opportunity After Strong Runs

The market for obesity and weight management drugs is attracting a lot of interest lately in the United States. Patients are gradually understanding the benefits of obesity drugs like Novo Nordisk's NVO Wegovy.

3 Stocks to Focus on as Demand for Obesity Drugs Booms

Danish drugmaker Novo Nordisk aims to bring its blockbuster weight-loss drug Wegovy to India in 2026, after securing regulatory approvals and ensuring it has enough supply to meet demand, a top company official told Reuters.

Novo Nordisk India head eyes 2026 Wegovy launch, warns against copycats

Amgen

The companies that already have obesity drugs can't keep up with the demand for their treatments, and the demand for the drugs is only likely to become more intense. That's because over 42% of the U.S. population was obese as of 2020, while the pervasive publicity around these drugs will make them more popular, and the social and political pressure for insurers to cover the treatments will become more intense.

3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals

Novo Nordisk has the income flow to pay a dividend for the long term. It also has a pipeline full of candidates to keep the growth going.

Is Novo Nordisk a Good Passive Income Stock?

Ozempic, Wegovy and other diabetes/weight loss drugs were prescribed more than 9 million times in the US during the fourth quarter of 2022, according to a new report.  A Trilliant Health analysis of insurance claims from about 300 million Americans found that prescriptions for the drugs quadrupled from early 2020 to the end of 2022.

US prescriptions for Ozempic and other weight loss drugs surged to 9 million in 4Q 2022

Novo Nordisk (NYSE:NVO)'s stellar growth is unlikely to slow this year, according to Stifel, which was updating its views after a call with the Danish pharma's management. “Our main takeaway is that we should not expect any inflexion in the strong growth momentum that it had year-to-date,” said the broker.

Novo Nordisk Wegovy surge to continue, says Stifel

The data confirms the rise in demand for GLP-1s, which have fueled a frenzy among Americans and on Wall Street for their ability to cause weight loss.

Ozempic, Wegovy drug prescriptions hit 9 million, surge 300% in under three years

High-quality dividend stocks frequently produce market-beating returns over the long term. Eli Lilly and Novo Nordisk are two blue-chip dividend stocks with rock-solid payouts and strong growth prospects.

News for Novo Nordisk Stock (NVO)